2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private PlacementPsyched Wellness Commences Pre-Clinical Trials of Amanita MuscariaHavn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an
Back

Compass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The Nasdaq

Sep 1, 2020 • 7:25 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle.

Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading psychedelic therapy company is a high-profile opportunity that is backed by tech billionaire Peter Thiel and lead investor Christian Angermayer.

When compared to its peers, we believe that Compass represents an advanced opportunity that is focused on developing psychedelic therapies for the treatment of mental illnesses such as depression. The company was founded almost four years ago and has been nothing short of an execution story. Compass plans to raise $100 million in the initial public offering (IPO) and plans to use the proceeds to advance its therapies through Food and Drug Administration (FDA) clinical trials.

In 2018, Compass announced that the FDA had granted it breakthrough therapy status, which expedited the development process and puts the company in a league of its own.

In the public offering filing, Compass said that early signals from academic studies that use formulations of psilocybin have shown that psilocybin therapy could improve outcomes for patients that suffer from depression. Although studies that were highlighted by Compass analyzed products that were not developed by it, we are favorable on the data that was highlighted from the study.

According to data from Crunchbase, Compass has raised more than $115 million since inception and has one of the strongest balance sheets when compared to other companies in the sector. Compass’s largest shareholder is psychedelic drug firm Atai Life Sciences AG, which is controlled by Angermayer, which has invested in several compounds that have been studied for treatment of mental illness and opioid addiction.

We are favorable on the relationship that Compass has with Atai and will monitor how both stories continue to evolve. Going forward, we expect Compass’ offering to generate significant interest and is an opportunity to be aware of.

If you are interested in learning more about Compass Pathways, please email support@mushroomstocks.com to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link